155 related articles for article (PubMed ID: 26759969)
1. Strategies for price reduction of HIV medicines under a monopoly situation in Brazil.
Chaves GC; Hasenclever L; Osorio-de-Castro CG; Oliveira MA
Rev Saude Publica; 2015; 49():. PubMed ID: 26759969
[TBL] [Abstract][Full Text] [Related]
2. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
3. Examining the production costs of antiretroviral drugs.
Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
[TBL] [Abstract][Full Text] [Related]
4. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.
Waning B; Kaplan W; King AC; Lawrence DA; Leufkens HG; Fox MP
Bull World Health Organ; 2009 Jul; 87(7):520-8. PubMed ID: 19649366
[TBL] [Abstract][Full Text] [Related]
5. Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP).
Juneja S; Gupta A; Moon S; Resch S
PLoS One; 2017; 12(5):e0177770. PubMed ID: 28542239
[TBL] [Abstract][Full Text] [Related]
6. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Rosenberg ST
Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
[TBL] [Abstract][Full Text] [Related]
7. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.
Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA
Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770
[TBL] [Abstract][Full Text] [Related]
8. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand.
Ford N; Wilson D; Costa Chaves G; Lotrowska M; Kijtiwatchakul K
AIDS; 2007 Jul; 21 Suppl 4():S21-9. PubMed ID: 17620749
[TBL] [Abstract][Full Text] [Related]
9. Access to hepatitis C virus treatment: Lessons from implementation of strategies for increasing access to antiretroviral treatment.
Assefa Y; Hill PS; Williams OD
Int J Infect Dis; 2018 May; 70():65-68. PubMed ID: 29550446
[TBL] [Abstract][Full Text] [Related]
10. Public procurement of hepatitis C medicines in Brazil from 2005 to 2015.
Chaves GC; Castro CGSO; Oliveira MA
Cien Saude Colet; 2017 Aug; 22(8):2527-2538. PubMed ID: 28793069
[TBL] [Abstract][Full Text] [Related]
11. Prices & availability of common medicines at six sites in India using a standard methodology.
Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R
Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011.
Luo J; Oliveira MA; Ramos MB; Maia A; Osorio-de-Castro CG
BMC Public Health; 2014 Apr; 14():367. PubMed ID: 24735589
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral purchasing and prescription practices in Mexico: constraints, challenges and opportunities.
Chaumont C; Bautista-Arredondo S; Calva JJ; Bahena-González RI; Sánchez-Juárez GH; González de Araujo-Muriel A; Magis-Rodríguez C; Hernández-Ávila M
Salud Publica Mex; 2015; 57 Suppl 2():s171-82. PubMed ID: 26545133
[TBL] [Abstract][Full Text] [Related]
14. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia.
Babar ZU; Ibrahim MI; Singh H; Bukahri NI; Creese A
PLoS Med; 2007 Mar; 4(3):e82. PubMed ID: 17388660
[TBL] [Abstract][Full Text] [Related]
15. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
16. Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System.
Scopel CT; Chaves GC
Cad Saude Publica; 2016 Dec; 32(11):e00113815. PubMed ID: 27925025
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
[TBL] [Abstract][Full Text] [Related]
18. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
[TBL] [Abstract][Full Text] [Related]
19. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement.
Beall RF; Kuhn R; Attaran A
Health Aff (Millwood); 2015 Mar; 34(3):493-501. PubMed ID: 25732501
[TBL] [Abstract][Full Text] [Related]
20. Negotiating antiretroviral drug prices: the experience of the Andean countries.
Seoane-Vazquez E; Rodriguez-Monguio R
Health Policy Plan; 2007 Mar; 22(2):63-72. PubMed ID: 17299024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
